The approval of Veppanu, also known as vepdegestrant, is more than another breast-cancer drug launch. It is the first time the U.S. Food and Drug Administration has cleared a medicine built on PROTAC technology, a drug-design strategy that seeks not merely to block disease-causing proteins, but to remove them from the cell.

On May 1, 2026, the FDA approved Veppanu for adults with estrogen receptor-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer whose disease has progressed after at least one line of endocrine therapy. The drug, developed by Arvinas with partner Pfizer, is a once-daily oral therapy and the first FDA-approved PROteolysis TArgeting Chimera, or PROTAC.
For a field that began as an academic experiment more than two decades ago, the approval is a long-awaited validation. It also arrives with caveats. Veppanu’s label is narrower than the full breast-cancer population first envisioned, and analysts have questioned how large its near-term commercial opportunity will be. But as a proof of concept, the drug gives targeted protein degradation something it had lacked until now: regulatory confirmation that the modality can produce an approved medicine.

What PROTACs Are
A conventional small-molecule drug usually works by binding to a protein and inhibiting its activity. That strategy has produced many important medicines, but it has limits. Some proteins lack obvious binding pockets. Others perform scaffolding functions that are not easily blocked by an inhibitor. And in cancer, cells can sometimes overcome inhibition by producing more of the target protein or mutating it.
A PROTAC takes a different approach. It is a heterobifunctional molecule: one end binds the disease-related protein, the other recruits an E3 ubiquitin ligase, part of the cell’s natural protein-disposal machinery. By bringing the target protein and ligase together, the PROTAC induces tagging of the target with ubiquitin. The cell’s proteasome then destroys the tagged protein.
The idea is powerful because the drug does not need to sit permanently on the target. In principle, one PROTAC molecule can trigger degradation of multiple protein molecules. That gives the approach an “event-driven” character, distinct from the “occupancy-driven” logic of classic inhibitors.
The appeal is especially clear in cancer. A degrader can eliminate both the catalytic and non-catalytic functions of a target protein. It may also overcome resistance mechanisms that make simple inhibition less effective. But the same features that make PROTACs attractive also make them difficult: they are often larger and more chemically complex than traditional oral small molecules, and their activity depends on forming a productive three-part complex among the drug, the target, and the E3 ligase.

A Two-Decade Scientific Arc
The PROTAC concept traces back to a 2001 paper by Kathleen Sakamoto, Kyung B. Kim, Akiko Kumagai, Frank Mercurio, Craig Crews and Raymond Deshaies, who described chimeric molecules that could recruit a target protein to the Skp1-Cullin-F-box ubiquitination machinery for degradation.
In the early years, PROTACs were more chemical-biology tools than plausible medicines. Many first-generation molecules used peptide components and were not optimized for oral drug-like properties. The field began to accelerate as researchers developed more usable ligands for E3 ligases, especially VHL and cereblon, enabling fully small-molecule degraders.
Several academic groups became central to the field. Craig Crews at Yale helped drive the concept from laboratory tool toward therapeutic platform and later founded Arvinas. Raymond Deshaies, now associated with Amgen, was a key co-inventor of the early concept. Alessio Ciulli and collaborators made major contributions to VHL ligand design and ternary-complex biology, helping clarify why productive protein-protein interactions are often as important as simple binding affinity.
By the mid-2010s, the field had moved from curiosity to investment theme. The rise of targeted protein degradation coincided with growing industry interest in “undruggable” targets, precision oncology, chemical biology and new small-molecule modalities. Arvinas, C4 Therapeutics, Kymera Therapeutics, Nurix Therapeutics and others emerged as specialized degrader companies, while larger drugmakers began signing partnerships or building internal programs.

Why Veppanu Matters
Veppanu’s approval matters because it answers a question that hung over the field for years: can a PROTAC become a real medicine?
The FDA’s answer is now yes.
Veppanu is an oral estrogen-receptor degrader. It is approved for patients with ESR1-mutated ER-positive/HER2-negative advanced or metastatic breast cancer, a setting where resistance to endocrine therapy remains a major problem. The FDA also approved the Guardant360 CDx blood test as a companion diagnostic to identify patients with ESR1 mutations who may be eligible for the drug.
Still, the approval is not a sweeping victory without qualification. The pivotal VERITAC-2 study supported approval in the ESR1-mutated population, but reports noted that the broader intent-to-treat analysis did not show the same statistically significant benefit. BioSpace reported that Veppanu improved progression-free survival by 43% versus AstraZeneca’s Faslodex in the ESR1-mutated group, while the intent-to-treat analysis failed to reach statistical significance.
That distinction is important. The first approved PROTAC is not entering the market as a broad breast-cancer drug for all ER-positive patients. It is entering as a biomarker-defined therapy in a resistant, advanced setting. That may limit near-term sales, but it also reflects the precision-medicine path many new oncology modalities must follow: prove value first in a genetically or biologically defined population, then expand if the data allow.

The Industry Landscape
The targeted protein degradation field is now crowded, but still young.
Arvinas remains the symbolic leader because it brought the first PROTAC to approval. Beyond Veppanu, the company has highlighted programs in oncology and neuroscience, including LRRK2 degradation for Parkinson’s disease and related disorders, and additional oncology targets such as KRAS and HPK1. PharmaVoice reported that Arvinas is shifting attention toward newer programs even as Veppanu enters the market.
Pfizer gained exposure to PROTACs through its partnership with Arvinas. Its role illustrates how large pharma companies often approach emerging modalities: let specialized biotechs take early technology risk, then partner when clinical validation appears closer.
Kymera Therapeutics has become one of the most closely watched companies outside oncology. Its strategy has increasingly emphasized immunology and inflammation, including KT-621, an oral STAT6 degrader in Phase 2 testing for atopic dermatitis and asthma. Kymera also has partnered IRAK4 degrader work with Sanofi.
Nurix Therapeutics is advancing targeted protein degradation programs in cancer and autoimmune disease, including degraders of BTK and programs connected to CBL-B, an E3 ligase involved in immune-cell regulation.
C4 Therapeutics has focused on oncology degraders, including cemsidomide, an IKZF1/3 degrader, while also exploring degrader-antibody approaches through partnerships. The company’s trajectory also shows the sector’s financial discipline: not every degrader program survives, and companies have had to prioritize assets with clearer clinical and commercial paths.
Large pharmaceutical companies including Bristol Myers Squibb, Novartis, Roche, Sanofi, Amgen and others have also invested in protein degradation through partnerships, acquisitions or internal programs. The field now includes not only PROTACs but also molecular glues, LYTACs, degrader-antibody conjugates, autophagy-targeting degraders and other approaches.

Why Investors Care
The commercial case for PROTACs rests on three possibilities.
First, degraders may reach targets that traditional inhibitors cannot. Many disease-relevant proteins have historically been considered undruggable because they lack suitable pockets or depend on scaffolding interactions rather than enzymatic activity.
Second, degraders may offer deeper or more durable pharmacology. Eliminating a protein can produce effects that blocking one active site cannot.
Third, degraders may expand beyond oncology. If companies can solve tissue distribution, safety and dosing challenges, the modality could become relevant in immunology, inflammatory disease, neurodegeneration and rare disease.
Market forecasts vary widely because the category is still early. Mordor Intelligence estimated the targeted protein degradation market at $0.65 billion in 2025, growing to $1.60 billion by 2030, a compound annual growth rate of about 20.75%. MarketsandMarkets projected a larger long-term opportunity, forecasting the market could reach $9.85 billion by 2035 from $0.48 billion in 2025, with growth driven by capital investment, partnerships and development across multiple indications.
The gap between those estimates reflects uncertainty. Veppanu proves the modality can cross the FDA finish line. It does not prove that PROTACs will automatically become a multibillion-dollar class. That will require repeated approvals, clearer superiority over existing drugs and evidence that degraders can succeed outside narrow oncology niches.
Scientific and Commercial Challenges
The biggest challenge is chemistry. PROTACs are often large molecules, and large molecules can struggle with oral absorption, cell permeability and tissue penetration. Medicinal chemists have made major progress, but designing a degrader remains more complex than optimizing a standard inhibitor.
A second challenge is selectivity. PROTACs can be exquisitely selective, but they can also produce unexpected degradation if the ternary complex recruits unintended proteins. This makes proteomics and safety profiling essential.
A third challenge is E3 ligase biology. Most clinical degraders rely on a small set of E3 ligases, especially cereblon and VHL. The human body has hundreds of E3 ligases, but relatively few have drug-like ligands suitable for therapeutic development. Expanding the E3 toolbox could unlock tissue-specific degradation, better safety and broader disease applications.
A fourth challenge is commercial positioning. A degrader must do more than sound scientifically elegant. It must beat or complement existing standards of care. In breast cancer, Veppanu will compete in a landscape that already includes endocrine therapies, SERDs, CDK4/6 inhibitors, PI3K/AKT/mTOR pathway drugs and antibody-drug conjugates. Its uptake will depend on label, tolerability, sequencing, physician comfort, biomarker testing and eventual pricing.

Future Directions
The next phase of PROTAC development will likely move in several directions.
One is next-generation oncology degraders against targets such as KRAS, BRAF, androgen receptor, BTK, CDK family members and transcriptional regulators. The goal is to address resistance and remove proteins that inhibitors only partially control.
Another is immunology and inflammation, where oral degraders could compete with injectable biologics if they can deliver biologic-like pathway suppression with small-molecule convenience. Kymera’s STAT6 program is one of the clearest examples of this ambition.
A third is neurodegeneration. The brain has long been difficult territory for large or complex small molecules. But if blood-brain-barrier-penetrant degraders can safely reduce proteins such as LRRK2 or other disease-associated targets, protein degradation could become a major new approach in diseases such as Parkinson’s, Alzheimer’s or ALS.
A fourth is targeted delivery. Degrader-antibody conjugates, tissue-targeted degraders and other delivery strategies could help solve exposure and safety problems by concentrating degradation activity in the right cells.
A fifth is new degradation machinery. PROTACs use the ubiquitin-proteasome system, but newer approaches attempt to use lysosomes, autophagy or extracellular protein clearance. These could expand degradation to membrane proteins, secreted proteins and targets outside the reach of classic intracellular PROTACs.

The Outlook
Veppanu’s approval is a milestone, not a finish line.
For patients with ESR1-mutated advanced breast cancer, it adds a new oral treatment option after endocrine therapy resistance. For Arvinas, it validates a platform the company has spent more than a decade building. For the broader biotech industry, it marks the first regulatory proof that a designed protein degrader can become an approved drug.
But the next question is harder: can PROTACs become a broadly useful therapeutic class, or will they remain a specialized solution for selected targets?
The answer will depend on whether the field can show that degradation is not just different, but better. Better efficacy. Better resistance profiles. Better tolerability. Better convenience. Better reach into diseases where traditional pharmacology has failed.
The first PROTAC approval gives the field a credible starting point. The second, third and fourth approvals will determine whether targeted protein degradation becomes a durable pillar of drug discovery or a narrower chapter in oncology innovation. For now, Veppanu has done what no PROTAC had done before: it turned a once-radical chemical-biology idea into an FDA-approved medicine.